RLAY · NASDAQ
Relay Therapeutics (RLAY) Stock Price & Fundamentals
Relay Therapeutics (RLAY) closed at $392.77 on Oct 9, 2026, up 0.77% from the previous close of $389.78.
Share price, past year
1Y +16.42%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $392.77 |
| Sep 30, 2026 | $380.77 |
| Aug 31, 2026 | $385.62 |
| Jul 31, 2026 | $377.14 |
| Jun 30, 2026 | $356.05 |
| May 29, 2026 | $356.59 |
| Apr 30, 2026 | $338.00 |
| Mar 31, 2026 | $349.27 |
| Feb 27, 2026 | $372.33 |
| Jan 30, 2026 | $349.07 |
| Dec 31, 2025 | $370.53 |
| Nov 28, 2025 | $351.64 |
| Oct 31, 2025 | $340.45 |
Key statistics
- Market cap
- $85.83B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.56
- Revenue (TTM)
- $10.35M
- Net income (TTM)
- −$286.04M
- Shares outstanding
- 218.5M
- Dividend yield
- —
- 52-week range
- $332.41 – $392.77
Relay Therapeutics's market cap is $85.83B, based on a share price of $392.77 and 218.5M shares outstanding as of Jun 30, 2026.
Financials
Relay Therapeutics reported revenue of $15.36M for fiscal 2025, up 53.44% from fiscal 2024.
Relay Therapeutics reported a net loss of $276.48M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $15.36M | +53.4% | −$276.48M | −1,800.6% | −$1.61 | −$235.87M |
| FY2024ended Dec 31, 2024 | $10.01M | −60.8% | −$337.71M | −3,374.7% | −$2.36 | −$251.13M |
| FY2023ended Dec 31, 2023 | $25.55M | +1,749.8% | −$341.97M | −1,338.7% | −$2.79 | −$304.44M |
| FY2022ended Dec 31, 2022 | $1.38M | −54.4% | −$290.51M | −21,036.1% | −$2.59 | −$238.55M |
| FY2021ended Dec 31, 2021 | $3.03M | −96.3% | −$363.87M | −12,012.9% | −$3.82 | −$77.88M |
| FY2020ended Dec 31, 2020 | $82.65M | — | −$52.41M | −63.4% | −$5.40 | −$104.42M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $350.00K | −$83.71M | −$0.41 |
| Q1 FY2026ended Mar 31, 2026 | $3.00M | −$73.29M | −$0.41 |
| Q4 FY2025ended Dec 31, 2025 | $7.00M | −$54.89M | −$0.31 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$74.15M | −$0.43 |
| Q2 FY2025ended Jun 30, 2025 | $677.00K | −$70.38M | −$0.41 |
| Q1 FY2025ended Mar 31, 2025 | $7.68M | −$77.07M | −$0.46 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$76.00M | −$0.42 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$88.11M | −$0.63 |
Company profile
- Name
- Relay Therapeutics, Inc.
- Ticker
- RLAY
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 60 Hampshire Street, Cambridge, MA 02139
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001812364
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jun 9, 2026
- May 21, 2026
- May 19, 2026
- May 5, 2026
- May 5, 2026
- Apr 27, 2026
Frequently asked questions
What is Relay Therapeutics's stock price?
Relay Therapeutics (RLAY) closed at $392.77 on Oct 9, 2026, up 0.77% from the previous close of $389.78.
What is Relay Therapeutics's market cap?
Relay Therapeutics's market cap is $85.83B, based on a share price of $392.77 and 218.5M shares outstanding as of Jun 30, 2026.
How much revenue does Relay Therapeutics make?
Relay Therapeutics reported revenue of $15.36M for fiscal 2025, up 53.44% from fiscal 2024.
Does Relay Therapeutics pay a dividend?
Relay Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Relay Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures